These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 20065123)

  • 1. Positron emission tomography-computed tomography in paraneoplastic neurologic disorders: systematic analysis and review.
    McKeon A; Apiwattanakul M; Lachance DH; Lennon VA; Mandrekar JN; Boeve BF; Mullan B; Mokri B; Britton JW; Drubach DA; Pittock SJ
    Arch Neurol; 2010 Mar; 67(3):322-9. PubMed ID: 20065123
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Occult malignancy in patients with suspected paraneoplastic neurologic syndromes: value of positron emission tomography in diagnosis.
    Patel RR; Subramaniam RM; Mandrekar JN; Hammack JE; Lowe VJ; Jett JR
    Mayo Clin Proc; 2008 Aug; 83(8):917-22. PubMed ID: 18674476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imaging Workup of Suspected Classical Paraneoplastic Neurological Syndromes: A Systematic Review and Retrospective Analysis of
    Sundermann B; Schröder JB; Warnecke T; Heindel W; Schäfers M; Weckesser M; Buerke B
    Acad Radiol; 2017 Oct; 24(10):1195-1202. PubMed ID: 28551401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utility of F-18 FDG PET/CT in screening for paraneoplastic neurological syndromes.
    Matsuhisa A; Toriihara A; Kubota K; Makino T; Mizusawa H; Shibuya H
    Clin Nucl Med; 2012 Jan; 37(1):39-43. PubMed ID: 22157026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Whole-body 18F FDG positron emission tomography/computed tomography evaluation of patients with uveal metastasis.
    Patel P; Finger PT
    Am J Ophthalmol; 2012 Apr; 153(4):661-8. PubMed ID: 22264690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Limited screening with versus without (18)F-fluorodeoxyglucose PET/CT for occult malignancy in unprovoked venous thromboembolism: an open-label randomised controlled trial.
    Robin P; Le Roux PY; Planquette B; Accassat S; Roy PM; Couturaud F; Ghazzar N; Prevot-Bitot N; Couturier O; Delluc A; Sanchez O; Tardy B; Le Gal G; Salaun PY;
    Lancet Oncol; 2016 Feb; 17(2):193-199. PubMed ID: 26672686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lymph node metastasis of squamous cell carcinoma from an unknown primary in the upper and middle neck: Impact of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography.
    Deron PB; Bonte KM; Vermeersch HF; Van de Wiele C
    Cancer Biother Radiopharm; 2011 Jun; 26(3):331-4. PubMed ID: 21711095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined [18F]Fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET/CT) for detection of recurrent, 131I-negative thyroid cancer.
    Finkelstein SE; Grigsby PW; Siegel BA; Dehdashti F; Moley JF; Hall BL
    Ann Surg Oncol; 2008 Jan; 15(1):286-92. PubMed ID: 17882493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Positron emission tomography combined with computed tomography as a screening tool for occult malignancy in patients with unprovoked venous thromboembolism: an observational study.
    Chauchard M; Benali K; Papo T; Sacre K
    Medicine (Baltimore); 2014 Nov; 93(21):e110. PubMed ID: 25380083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Accuracy of FDG-PET/CT and paraneoplastic antibodies in diagnosing cancer in paraneoplastic neurological syndromes.
    Vatankulu B; Yilmaz Aksoy S; Asa S; Sager S; Sayman HB; Halac M; Sonmezoglu K
    Rev Esp Med Nucl Imagen Mol; 2016; 35(1):17-21. PubMed ID: 26260889
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Whole-Body
    Sheikhbahaei S; Marcus CV; Fragomeni RS; Rowe SP; Javadi MS; Solnes LB
    J Nucl Med; 2017 Jul; 58(7):1031-1036. PubMed ID: 27980049
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 18F-fluorodeoxyglucose positron emission tomography-computed tomography for suspected recurrent papillary thyroid cancer: early experience at Sunnybrook Health Sciences Centre.
    Dahele M; Ung YC; Ehrlich L; Silverberg J; Balogh J; Wong CS
    J Otolaryngol Head Neck Surg; 2008 Oct; 37(5):712-7. PubMed ID: 19128681
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Positron emission tomography combined with diagnostic chest computed tomography enhances detection of regional recurrence after stereotactic body radiation therapy for early stage non-small cell lung cancer.
    Ebright MI; Russo GA; Gupta A; Subramaniam RM; Fernando HC; Kachnic LA
    J Thorac Cardiovasc Surg; 2013 Mar; 145(3):709-15. PubMed ID: 23317944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Positron emission tomography-computed tomography compared with invasive mediastinal staging in non-small cell lung cancer: results of mediastinal staging in the early lung positron emission tomography trial.
    Darling GE; Maziak DE; Inculet RI; Gulenchyn KY; Driedger AA; Ung YC; Gu CS; Kuruvilla MS; Cline KJ; Julian JA; Evans WK; Levine MN
    J Thorac Oncol; 2011 Aug; 6(8):1367-72. PubMed ID: 21587082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paraneoplastic immune-mediated neurological effects of systemic cancers.
    Sioka C; Fotopoulos A; Kyritsis AP
    Expert Rev Clin Immunol; 2014 May; 10(5):621-30. PubMed ID: 24665890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [(18)F-FDG PET/CT in the evaluation of patients suspected of paraneoplastic neurological syndrome].
    García Vicente AM; Vega Caicedo CH; Mondéjar Solís R; de Ayala Fernández JÁ; Garrido Robles JA; Pena Pardo FJ; Muñoz Pasadas M; Del Saz Saucedo P; Jiménez Londoño GA; León Martín A; Soriano Castrejón Á
    Rev Esp Med Nucl Imagen Mol; 2015; 34(4):236-43. PubMed ID: 25864422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Positron emission tomography/computed tomography for lung cancer staging].
    Ladrón de Guevara H D; Furnaro L F; Yévenes A S; Clavero R JM; Lazo P D; Rodríguez D P; Piottante B A; Pefaur D R; Pardo B C
    Rev Med Chil; 2015 Jan; 143(1):22-9. PubMed ID: 25860265
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 18-fluorodeoxyglucose positron emission tomography enhances computed tomography diagnosis of malignant intraductal papillary mucinous neoplasms of the pancreas.
    Sperti C; Bissoli S; Pasquali C; Frison L; Liessi G; Chierichetti F; Pedrazzoli S
    Ann Surg; 2007 Dec; 246(6):932-7; discussion 937-9. PubMed ID: 18043094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FDG-PET improves tumour detection in patients with paraneoplastic neurological syndromes.
    Younes-Mhenni S; Janier MF; Cinotti L; Antoine JC; Tronc F; Cottin V; Ternamian PJ; Trouillas P; Honnorat J
    Brain; 2004 Oct; 127(Pt 10):2331-8. PubMed ID: 15361417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Impact of positron emission tomography on clinical management of potentially resectable non-small-cell lung cancer: a French prospective multicenter study].
    Margery J; Milleron B; Vaylet F; Grahek D; Lebeau B; Mangiapan G; Bonardel G; de Labriolle-Vaylet C; Meignan M; Carette MF; Talbot JN; Housset B
    Rev Pneumol Clin; 2010 Oct; 66(5):313-20. PubMed ID: 21087727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.